ModernMedicine Resource Center More Topics

Fragile Skin Therapies

Psoriasis Gene to Clinic Congress HighlightsExperts from around the world will gather in London at the Psoriasis from Gene to Clinic Congress to present and discuss the most current developments in the understanding of psoriasis and the evidence that will steer future clinical decision making. Watch here for highlights.
New products for November 2017A round-up of the latest products hitting the dermatology market including treatment for eczema and wounds, plus care for rejuvenating procedures.
In atopic dermatitis, are you employing the therapeutic ladder approach?Treatment for atopic dermatitis isn’t always straightforward. In this article, a physician outlines treatment approaches.
Atopic dermatitis: Biologics to watch in 2018In this article, we take a look at the development of new treatments for atopic dermatitis.
Patch testing remains underreported
Patch testing remains underreportedPatch testing for allergic contact dermatitis in the pediatric population is performed at a higher rate than previously reported, but still grossly underreported, according to a study of the Pediatric Contact Dermatitis Registry.
Atopic dermatitis associated with different bacteria depending on disease severityNIH investigators find that Staphylococcus epidermidis is predominant in less severe cases, while Staphylococcus aureus is associated with patients who have more severe disease.
Psoriasis and atopic dermatitis respond to IL-17 creamNitric oxide-releasing cream that targets IL-17 moving toward clinical trials.
Gene mutation identified in atopic dermatitisA new study shows that mutations in the gene CARD11 are associated with severe atopic disease.
House dust mites and severe atopic dermatitis: A new connectionPatients with severe atopic dermatitis who have lower serum vitamin D levels have a high sensitivity to house dust mites which can aggravate their condition, a new study shows.
IL-31 pathway may lead to new treatments for pruritusIn early research, subcutaneous nemolizumab significantly reduced pruritus in moderate-to-severe atopic dermatitis adult patients.